Last reviewed · How we verify
topiramate; almotriptan malate
Topiramate and almotriptan malate, marketed by Janssen-Ortho LLC, are established treatments in their respective therapeutic areas with a strong market presence. A key strength is the key composition patent, which is set to expire in 2028, providing a period of exclusivity and protection against generic competition. The primary risk is the eventual patent expiry, which could lead to increased competition from generics and potential revenue erosion.
At a glance
| Generic name | topiramate; almotriptan malate |
|---|---|
| Sponsor | Janssen-Ortho LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACT Therapy for HF Migraine (NA)
- Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine (PHASE4)
- Detoxification and Treatment of Subjects With Medication Overuse Headache (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- topiramate; almotriptan malate CI brief — competitive landscape report
- topiramate; almotriptan malate updates RSS · CI watch RSS
- Janssen-Ortho LLC portfolio CI